Cardinal Health Faces FDA Class II Recall for RECOMBINATE Due to Repeated Temperature Excursions
Cardinal Health Inc. has initiated a Class II recall for RECOMBINATE, Antihemophilic Factor (Recombinant), 5 mL vials, impacting three units nationwide. The recall, D-0573-2025, stems from CGMP deviations related to product exposure to temperatures outside labeled storage requirements. This marks a concerning pattern, as Cardinal Health faced a similar temperature excursion recall in 2021, signaling systemic cold chain vulnerabilities for procurement and supply chain leaders.
FDA Identifies Critical CGMP Deviations in Cardinal Health's RECOMBINATE Distribution
Cardinal Health Inc., operating from its Dublin, OH facility at 7000 Cardinal Pl, Dublin, OH 43017-1091, has initiated a Class II recall (D-0573-2025) for three units of RECOMBINATE, Antihemophilic Factor (Recombinant), 5 mL vials. This critical therapeutic, manufactured by Takeda Pharmaceuticals USA in Cambridge, MA 02142, was found to have been exposed to temperatures outside its labeled storage requirements. Such temperature excursions constitute a direct deviation from Current Good Manufacturing Practices (CGMP), compromising product integrity and patient safety. The affected lots are TRB23802AC, expiring on March 18, 2026, and TRA22804AA, expiring on October 18, 2025. The recall, initiated voluntarily by Cardinal Health on July 30, 2025, and classified by the FDA on August 7, 2025, is ongoing with nationwide distribution within the U.S. This incident means procurement directors must immediately assess their reliance on Cardinal Health for temperature-sensitive biologics, as the integrity of the cold chain for these critical products is paramount. Any compromise can lead to efficacy loss, posing significant risks to patient outcomes and substantial financial and reputational damage to the entire supply chain.
Cardinal Health's Distribution Role and Implications for Biologic Supply Chains
Cardinal Health Inc., a major player in healthcare distribution, is the recalling firm in this event, indicating that the CGMP deviations related to temperature control occurred within their distribution network, specifically from their Dublin, OH facility. While Takeda Pharmaceuticals USA manufactures RECOMBINATE, the responsibility for maintaining labeled storage conditions post-manufacture typically falls to the distributor. This distinction is crucial for regulatory affairs heads and supply chain VPs. The recall of RECOMBINATE, an Antihemophilic Factor (Recombinant), underscores the critical importance of robust environmental controls throughout the pharmaceutical supply chain, particularly for biologics that are highly sensitive to temperature fluctuations. For businesses sourcing critical medications, this event highlights that even with a reputable manufacturer like Takeda, the weakest link in the distribution chain can introduce significant risk. This necessitates a thorough re-evaluation of distributor qualification processes and ongoing audit programs to ensure compliance with stringent storage requirements for all distributed products, safeguarding both product efficacy and patient safety.
Supply Chain Vulnerabilities: Nationwide Exposure for Antihemophilic Factor (Recombinant)
The nationwide distribution pattern of the recalled RECOMBINATE units means that the potential impact, though limited to three specific units, extends across the entire U.S. healthcare system. Antihemophilic Factor (Recombinant) is a life-saving medication for individuals with hemophilia, making any recall, regardless of quantity, a serious concern for patient access and continuity of care. While the immediate impact of only three units being recalled may seem minimal, the underlying CGMP deviation points to a systemic vulnerability in Cardinal Health's cold chain management. For supply chain VPs, this incident necessitates a comprehensive review of all temperature-sensitive products distributed through Cardinal Health. The risk extends beyond RECOMBINATE; any biologic or pharmaceutical requiring strict temperature control could be similarly affected. Business development executives should note the potential for market disruption and the heightened demand for distributors with demonstrably robust cold chain capabilities. Proactive risk mitigation, including identifying and qualifying secondary distribution partners, becomes an urgent priority to prevent broader supply disruptions for critical therapies.
Identifying Alternative Suppliers for Antihemophilic Factor (Recombinant)
While the ChemLifeIntel Knowledge Graph does not explicitly list alternative suppliers for RECOMBINATE or specific Antihemophilic Factor (Recombinant) products, procurement directors must proactively explore the broader market for hemophilia treatments. The market for recombinant coagulation factors includes various manufacturers, though switching suppliers for biologics is a complex undertaking. It typically involves extensive product qualification, comparability studies, and potentially new regulatory submissions, which can incur significant costs and lengthy timelines. Companies like Bayer, Pfizer, CSL Behring, and Novo Nordisk are known producers of different antihemophilic factors, but their specific product portfolios and regulatory approvals would need careful evaluation for direct substitution. This recall underscores the necessity for procurement teams to maintain an active pipeline of qualified alternative suppliers for all critical raw materials and finished drug products, especially those with stringent storage requirements. Diversifying the supplier base and understanding the qualification timelines for each alternative is crucial for mitigating supply chain risks and ensuring uninterrupted patient access to essential medications.
Cardinal Health's Recurring Compliance Challenges with Temperature Control
This Class II recall for RECOMBINATE is not an isolated incident for Cardinal Health Inc. The company faced a similar Class II recall on June 2, 2021, for XIGDUO XR, also due to storage temperature excursions. This pattern of non-compliance related to environmental controls during product storage is a significant red flag for regulatory affairs heads and business development executives. A repeat offense for the same type of CGMP deviation suggests that previous corrective actions may have been insufficient or that systemic issues within Cardinal Health's quality management system for storage and distribution persist. This history indicates an elevated risk profile for Cardinal Health, potentially leading to more intensive scrutiny from the FDA. Such a trend can result in broader regulatory actions, including increased inspection frequency, stricter enforcement, or even limitations on distribution capabilities, which would significantly impact the reliability of supply for all products handled by Cardinal Health. Companies relying on Cardinal Health must factor this recurring risk into their supplier evaluations and risk management strategies.
Remediation Expectations and Future Regulatory Actions for Cardinal Health
Given the 'Ongoing' status of the RECOMBINATE recall, Cardinal Health Inc. is obligated to conduct a thorough root cause analysis to identify the precise reasons for the temperature excursions and implement comprehensive Corrective and Preventive Actions (CAPA). The FDA will closely monitor the effectiveness of these actions and the recall process itself. For regulatory affairs heads, this means Cardinal Health must provide robust evidence of its remediation efforts, including enhanced training, improved monitoring systems, and validated cold chain protocols. Failure to adequately address these systemic issues could lead to further regulatory enforcement, including potential Warning Letters or even consent decrees, which would severely impact Cardinal Health's operational freedom and market standing. Supply chain VPs should anticipate that future FDA inspections of Cardinal Health's facilities will likely focus heavily on cold chain management and overall CGMP compliance. Companies sourcing from Cardinal Health should proactively request detailed CAPA plans and evidence of their implementation to assess ongoing supply reliability and mitigate potential future disruptions.